CD34+/CD38 acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells

Authors


  • Takayuki Ikezoe contributed to the concept and design, interpreted and analyzed the data and wrote an article. Chie Nishioka performed all experiments and wrote an article. Mutsuo Furihata, Jing Yang, Satoshi Serada, and Tetsuji Naka, Sayo Kataoka and Atsuya Nobumoto performed the experiments. Akihito Yokoyama and Keiko Udaka provided important intellectual content

Abstract

To identify molecular targets in leukemia stem cells (LSCs), this study compared the protein expression profile of freshly isolated CD34+/CD38 cells with that of CD34+/CD38+ counterparts from individuals with acute myelogenous leukemia (n = 2, AML) using isobaric tags for relative and absolute quantitation (iTRAQ). A total of 98 proteins were overexpressed, while six proteins were underexpressed in CD34+/CD38 AML cells compared with their CD34+/CD38+ counterparts. Proteins overexpressed in CD34+/CD38 AML cells included a number of proteins involved in DNA repair, cell cycle arrest, gland differentiation, antiapoptosis, adhesion, and drug resistance. Aberrant expression of CD82, a family of adhesion molecules, in CD34+/CD38 AML cells was noted in additional clinical samples (n = 12) by flow cytometry. Importantly, down-regulation of CD82 in CD34+/CD38 AML cells by a short hairpin RNA (shRNA) inhibited adhesion to fibronectin via up-regulation of matrix metalloproteinases 9 (MMP9) and colony forming ability of these cells as assessed by transwell assay, real-time RT-PCR, and colony forming assay, respectively. Moreover, we found that down-regulation of CD82 in CD34+/CD38 AML cells by an shRNA significantly impaired engraftment of these cells in severely immunocompromised mice. Taken together, aberrant expression of CD82 might play a role in adhesion of LSCs to bone marrow microenvironment and survival of LSCs. CD82 could be an attractive molecular target to eradicate LSCs.

Ancillary